Home » Stocks » Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. (TNXP)

Stock Price: $0.667 USD -0.007 (-1.04%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $0.655 -0.012 (-1.74%) Oct 23, 7:58 PM

Stock Price Chart

Key Info

Market Cap 86.84M
Revenue (ttm) n/a
Net Income (ttm) -38.00M
Shares Out 130.28M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.667
Previous Close $0.674
Change ($) -0.007
Change (%) -1.04%
Day's Open 0.678
Day's Range 0.642 - 0.690
Day's Volume 2,980,003
52-Week Range 0.390 - 4.200

More Stats

Market Cap 86.84M
Enterprise Value 31.82M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 130.28M
Float 130.14M
EPS (basic) -1.69
EPS (diluted) -1.84
FCF / Share -0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 992,636
Short Ratio 0.12
Short % of Float 0.76%
Beta 1.54
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.65
Revenue n/a
Operating Income -38.11M
Net Income -38.00M
Free Cash Flow -32.72M
Net Cash 55.03M
Net Cash / Share 0.42
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -64.95%
ROE -114.46%
ROIC 5,100.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.00*
Low
3.00
Current: $0.667
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-28.83-26.32-21.29-38.97-48.16-27.66-10.89-6.66-3.38-1.93
Net Income-28.62-26.09-21.12-38.84-48.05-27.62-10.88-9.45-3.47-1.96
Shares Outstanding1.610.117.040.030.020.01----
Earnings Per Share-19.33-259.85-2,999.90-1,541.00-2,862.00-2,770.00-3,370.00-5,580.00-3,240.00-3,600.00
Operating Cash Flow-26.68-23.97-19.13-37.31-42.53-22.84-8.52-5.71-2.64-1.23
Capital Expenditures-0.02-0.01-0.01-0.07-0.24-0.32-0.02-0.04--0.03
Free Cash Flow-26.70-23.98-19.13-37.38-42.77-23.16-8.53-5.75-2.64-1.27
Cash & Equivalents11.3525.1325.5926.2143.1538.328.261.850.100.13
Total Debt0.01-----0.28-2.08-
Net Cash / Debt11.3425.1325.5926.2143.1538.327.981.85-1.970.13
Assets14.5626.3226.7527.5147.0239.548.742.120.430.18
Liabilities5.142.662.142.156.763.452.221.162.880.36
Book Value9.4223.6624.6225.3640.2636.096.510.96-2.45-0.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tonix Pharmaceuticals Holding Corp.
Country United States
Employees 16
CEO Seth Lederman

Stock Information

Ticker Symbol TNXP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TNXP

Description

Tonix Pharmaceuticals Holding, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) portfolio comprises small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300, a second live replicating vaccine candidate for the prevention of COVID-19 that employs bovin parainfluenza virus as the vector. In addition, the company's lead CNS candidate is TNX-102 SL, which is in Phase 3 development for the management of fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR (tianeptine oxalate controlled-release tablets) that is in Phase 1 development for depression; and TNX-1900, an intranasal oxytocin as a non-addictive treatment for migraine and cranio-facial pain. Additionally, its preclinical pipeline includes TNX-1600, a triple reuptake inhibitor for posttraumatic stress disorder; TNX-1500, a monoclonal antibody to prevent and treat organ transplant rejection and autoimmune conditions; and TNX 1700, a recombinant modified form of Trefoil Family Factor 2 to treat gastric and pancreatic cancers. The company was founded in 2007 and is based in New York, New York.